October 20, 2021 10:48 AM EDT
Deals
Pharma

'No ex­cuse': ICER de­ter­mines As­traZeneca's new mon­ey­mak­er Soliris is vast­ly over­priced

Nicole DeFeudis

Editor

The ink has bare­ly dried on As­traZeneca’s $39 bil­lion deal to swal­low Alex­ion back in Ju­ly. But in­de­pen­dent drug watch­dog ICER has been crunch­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times